Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient Care online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient Care

Release Date: June 30, 2017
Expiration Date: June 30, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient Care features a summary of clinical evidence guiding best practices in the treatment of patients with non–small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene, as well as case-based discussions of adverse event management, compliance with oral therapies, and counseling of patients awaiting molecular test results. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with EGFR mutation-positive NSCLC. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by nursing professionals engaged in the care of patients with lung cancers.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward nurses and other healthcare professionals with an interest in the treatment of lung cancers.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain current and emerging testing platforms in the context of emerging methods to overcome barriers associated with tumor biopsies in the field of lung cancer treatment
  2. Detail key counseling points to address with patients with lung cancer who are awaiting results from tumor tissue testing
  3. Describe current and emerging evidence concerning the use of EGFR-targeted strategies in frontline and relapsed advanced non–small-cell lung cancer (NSCLC) disease settings
  4. Apply best nursing practices to counsel patents with advanced NSCLC concerning the prevention, mitigation, and management of treatment-related toxicities

Faculty, Staff, and Planners' Disclosures

Faculty

Karen C. Lee, MSN, FNP-BC
Clinical Nurse Practitioner
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Consultant: Boehringer Ingelheim; Speakers Bureau: Pfizer, Bristol-Meyers Squibb, Boehringer Ingelheim, AstraZeneca

Benjamin P. Levy, MD
Assistant Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Washington, DC
Medical Director, Thoracic Oncology Program
at SKCC at Sibley Memorial Hospital
Washington DC

Disclosure: Consultant: Celgene, AstraZeneca, Eli Lilly, Genentech, Pfizer, Merck Speakers Bureau: Eli Lilly, Genentech

Ann Culkin, RN, OCN
Department of Nursing
Office Practice Nurse, Ambulatory, Thoracic Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Consultant: Creative Educational Concepts, CE Program consultant

Alexander Drilon, MD
Clinical Director, Developmental Therapeutics
Assistant Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center, New York, NY
 
 

Disclosure: Grant Research Support: Foundation Medicine; Other: Honoraria: Ignyta, Exelixis, Genentech/Roche, AstraZeneca, Blueprint Medicines, Loxo.

Jonathan W. Riess, MD, MS
Assistant Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA
 

Disclosure: Grant Research Support: Merck, Novartis, Millennium; Consultant: Celgene, Ariad, Clovis Oncology, Medtronic, and Abbvie

Christine H. Teklehaimanote, MSN, GNP-BC, ACHPN
University of California
Davis Medical Center
Sacramento, CA
 
 

Disclosure: No relevant financial relationships to disclose

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By